Patients with psoriasis have a 20% greater risk of organ-based comorbidities when compared with the general population.

Researchers have found that the hormone estradiol suppresses psoriasis, providing a basis for therapeutic potential.

The global prevalence of metabolic syndrome (MetS) among patients with psoriasis is 32%, researchers report online in the Journal of the...

Patient with psoriasis value skin clearance and symptom control as most important treatment outcomes, according to a new study.

Tildrakizumab treatment for psoriasis showed a significant improvement when used for difficult-to-treat areas.

Patients with psoriasis are at an increased risk of developing alopecia areata.

Research suggests there is a bi-directional relationship between psoriasis and non-alcoholic fatty liver disease (NAFLD). This...

Psoriasis patients, with and without psoriatic arthritis, self-report using analgesics more than those without the disease.